At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 10-09 16:00:00 EDT
16.65
+0.43
+2.65%
盘后16.71
+0.06+0.37%
19:30 EDT
High16.97Low16.12Vol849.43K
Open16.16D1 Closing16.22Amplitude5.24%
Mkt Cap2.22BTradable Cap2.15BTotal Shares133.05M
T/O14.18MT/O Rate0.66%Tradable Shares129.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

13D Filings
Dow Jones  ·  09-05
13D Filings
LB Pharmaceuticals Names Joseph Miller CFO
MT Newswires Live  ·  09-03
LB Pharmaceuticals Names Joseph Miller CFO
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch
Simply Wall St.  ·  08-26
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Simply Wall St.  ·  08-22
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Aurinia Shares Gains After Settling Patent Lawsuit with Teva
Dow Jones  ·  08-20
Aurinia Shares Gains After Settling Patent Lawsuit with Teva
Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
TIPRANKS  ·  08-20
Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
Aurinia settles patent litigation with Teva
TIPRANKS  ·  08-20
Aurinia settles patent litigation with Teva
Aurinia Settles Teva Patent Suit, Bars Generic Voclosporin Launch Until Dec. 7, 2036
Reuters  ·  08-20
Aurinia Settles Teva Patent Suit, Bars Generic Voclosporin Launch Until Dec. 7, 2036
Aurinia Pharmaceuticals - Teva May Launch Generic Voclosporin in U.S. no Earlier than December 7, 2036
THOMSON REUTERS  ·  08-20
Aurinia Pharmaceuticals - Teva May Launch Generic Voclosporin in U.S. no Earlier than December 7, 2036
Aurinia Pharmaceuticals - Continues Patent Litigation Against Multiple Generic Companies in New Jersey
THOMSON REUTERS  ·  08-20
Aurinia Pharmaceuticals - Continues Patent Litigation Against Multiple Generic Companies in New Jersey
Aurinia Settles Patent Litigation with Teva
THOMSON REUTERS  ·  08-20
Aurinia Settles Patent Litigation with Teva
CannaPharmaRx Q2 FY26 Net Loss Widens to USD 1.91 Million; Revenue Rises 19.26% to USD 276,218
Reuters  ·  08-19
CannaPharmaRx Q2 FY26 Net Loss Widens to USD 1.91 Million; Revenue Rises 19.26% to USD 276,218
Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital
Dow Jones  ·  08-08
Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital
RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
MT Newswires Live  ·  08-07
RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  08-06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Benzinga Earnings  ·  08-06
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans
Reuters  ·  08-06
Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans
Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Reuters  ·  08-06
Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M
TIPRANKS  ·  08-06
Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M
Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million
Reuters  ·  08-06
Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--